NEW YORK STOCK EXCHANGE, INC. · JNJ

-2.55% · -$6.48 · Vol 10.5M

Market closed · last close 4:00 PM ET · price as of 19:59:09 ET

Johnson & Johnson

Pharmaceuticals

$247.37

+ Add to watchlist

Card

Relationship Map

Veridion Score

Refresh

Score snapshot refresh in progress

Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS

HISTORY WINDOW BUILDING

AI Analysis

Sovereign

Why is JNJ moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move JNJ next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Volume / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Jul 15
Score
Score moved -1
63/NEUTRAL -> 62/BUY BIAS
Veridion score historySource
Jul 15
Volume
Unusual volume 1.2x
10.5M shares · -2.7%
Market volume scanSource
Jul 6
CongressSovereign
Ro Khanna purchase disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jul 6
CongressSovereign
Hon. Lloyd Doggett sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jul 6
CongressSovereign
Lloyd Doggett purchase disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jun 9
CongressSovereign
Ro Khanna sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
May 11
CongressSovereign
Ro Khanna purchase disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Apr 14
CongressSovereign
John Boozman sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt

Catalyst calendar

Dated receipts for JNJ are being assembled.

About Johnson & Johnson

PHARMACEUTICAL PREPARATIONS

Listed since

1944

Employees

141K

Country

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$250.09

Day high

$256.83

Day low

$246.05

Previous close

$253.85

52W high

$257.89

-4.08% from high

52W low

$246.05

11% of range

Market cap

$611.1B

P/E

22.31×

EPS

$11.09

Shares out

2.4B

Volume

10.5M

VWAP

$249.69

Price history computed in-house

-3.74%

SMA 50 $252.68 · below

SMA 200 $252.68 · below

52W position 11%

Veridion warehouse edge

Warehouse intelligence for JNJ.

Veridion Score

0: 581: 442: 523: 514: 735: 78

Congress 30d

Ro Khanna · Purchase

Insider activity

See Form 4 panel below.

13F holders

Vanguard

Receipt-backed holder profiles

Vanguard · $49.7B BlackRock · $52.2B State Street · $32.6B Bridgewater Associates · $170.3M

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.

Related public evidence

Relationship mapTrace receipt-backed holders and filings around JNJ.Congress disclosuresOpen receipt and filing context for JNJ.MethodologyReview score inputs, coverage rules, and limitations.

Data ledger

Quote and day range

Refresh interval: 30 seconds

Source: Market data

Veridion Score

Coverage building

Source: Veridion methodology

Chart and risk context

Daily bars with no missing-bar fill

Source: Market data

News and filings

Refresh intervals shown inside each panel

Source: Market news and federal filings

Financials

Statements refresh in progress

SEC Form 4 ledger

JNJ insider activity

Johnson & Johnson

Score

Coverage building

Pressure

Net selling

Filings

Buys / sells

0 / 1

Net value

-$2.4M

Insiders

Named filers

Wengel Kathryn E

EVP, Chief TO and Risk Officer

C-Suite

Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$2.4M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing date	Trade date	Insider	Title	Type	Price	Qty	Owned	Value	Receipt
2026-06-12	2026-06-11	Wengel Kathryn E	EVP, Chief TO and Risk Officer	sell	$241.15	10,000	114,288	$2.4M	SEC Form 4

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Congress · 90D

Congress filing snapshot refresh in progress

Federal contracts

JNJ contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for JNJ in this window.

Lobbying spend

JNJ lobbying filings, year to date.

Registered lobbying filings matched to Johnson & Johnson.

$5.3M

Refresh interval: 12hSource: LDA disclosure filings

Health Issues Budget/Appropriations Copyright/Patent/Trademark Law Enforcement/Crime/Criminal Justice Pharmacy Science/Technology Taxation/Internal Revenue Code Veterans Trade (domestic/foreign)Health IssuesHealth Issues Medicare/Medicaid Taxation/Internal Revenue Code Bankruptcy Trade (domestic/foreign)

Filing

$3.5M

JOHNSON & JOHNSON SERVICES INC

JOHNSON & JOHNSON SERVICES, INC.

Apr 20, 2026

Filing

$1.5M

JOHNSON & JOHNSON SERVICES INC

JOHNSON & JOHNSON SERVICES, INC.

Jan 20, 2026

Filing

$100.0K